Capitalize on the Scalable & Diverse Potential of iPSC-Derived Therapies By Defining Differentiation Protocols, Optimal Cell Line Selection & Optimizing Gene Engineering To Accelerate Successfully Into the Clinic

The explosion of excitement and investment in the iPSC field has ushered in a new era of cell therapy, with these cells establishing its place as the optimal starting material for cell therapies targeting cancer, autoimmune, cardiac disease and much more.

The iPSC-Derived Cell Therapies Summit is your dedicated forum exclusively focused on the common challenges across disease indications which are limiting the clinical translation of iPSC-based approaches for cell therapy, including safety concerns with differentiation protocols, lack of regulatory guidance, and licensing issues.

Get caught up to speed on this dynamic industry with expertise shared from the likes of Shoreline Biosciences, Kite Pharma, HeartSeed, and Exacis, to understand the broad applicability of iPSCs, advances in novel gene engineering approaches, and translational lessons learned to advance your pipeline to clinical success.

Leave this meeting with the knowledge and connections to landscape the clinical progression, outline GMP compliant processes for scale up, and share strategies to ensure consistency in starting material.

This is your opportunity to collaborate with 80+ iPSC senior level experts from biopharma and academia and be at the forefront of the future of cell therapy by joining the mission to develop safe, scalable and cost-effective iPSC-derived therapies.

To Know more visit: https://ter.li/e7gdu7